In most of the preclinical models discussed above, cDC1-targeting therapeutic vaccines delay tumor progression or metastasis, or even promote a better tumor control over a long time, but fail by themselves in inducing complete tumor rejection. This evidence concerns the gene MPPE1 and neoplasm.